229 related articles for article (PubMed ID: 25922341)
21. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney.
Onozato ML; Tojo A; Kobayashi N; Goto A; Matsuoka H; Fujita T
Nephrol Dial Transplant; 2007 May; 22(5):1314-22. PubMed ID: 17324946
[TBL] [Abstract][Full Text] [Related]
22. Mineralocorticoid receptor blockade inhibits accelerated atherosclerosis induced by a low sodium diet in apolipoprotein E-deficient mice.
Raz-Pasteur A; Gamliel-Lazarovich A; Gantman A; Coleman R; Keidar S
J Renin Angiotensin Aldosterone Syst; 2014 Sep; 15(3):228-35. PubMed ID: 23223089
[TBL] [Abstract][Full Text] [Related]
23. Adrenocorticotrophin-induced hypertension: effects of mineralocorticoid and glucocorticoid receptor antagonism.
Li M; Wen C; Fraser T; Whitworth JA
J Hypertens; 1999 Mar; 17(3):419-26. PubMed ID: 10100081
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis.
Sica DA
Heart Fail Rev; 2005 Jan; 10(1):23-9. PubMed ID: 15947888
[TBL] [Abstract][Full Text] [Related]
25. Activation of mineralocorticoid receptors in the rostral ventrolateral medulla is involved in hypertensive mechanisms in stroke-prone spontaneously hypertensive rats.
Nakagaki T; Hirooka Y; Matsukawa R; Nishihara M; Nakano M; Ito K; Hoka S; Sunagawa K
Hypertens Res; 2012 Apr; 35(4):470-6. PubMed ID: 22237482
[TBL] [Abstract][Full Text] [Related]
26. Excretion of electrolytes in Brown Norway and Fischer 344 rats: effects of adrenalectomy and of mineralocorticoid and glucocorticoid receptor ligands.
Marissal-Arvy N; Mormède P
Exp Physiol; 2004 Nov; 89(6):753-65. PubMed ID: 15364879
[TBL] [Abstract][Full Text] [Related]
27. Does glucocorticoid receptor blockade exacerbate tissue damage after mineralocorticoid/salt administration?
Rickard AJ; Funder JW; Morgan J; Fuller PJ; Young MJ
Endocrinology; 2007 Oct; 148(10):4829-35. PubMed ID: 17640982
[TBL] [Abstract][Full Text] [Related]
28. Mineralocorticoid receptor antagonists attenuate exaggerated exercise pressor reflex responses in hypertensive rats.
Downey RM; Mizuno M; Mitchell JH; Vongpatanasin W; Smith SA
Am J Physiol Heart Circ Physiol; 2017 Oct; 313(4):H788-H794. PubMed ID: 28733447
[TBL] [Abstract][Full Text] [Related]
29. Intestinal Mineralocorticoid Receptor Contributes to Epithelial Sodium Channel-Mediated Intestinal Sodium Absorption and Blood Pressure Regulation.
Nakamura T; Kurihara I; Kobayashi S; Yokota K; Murai-Takeda A; Mitsuishi Y; Morisaki M; Kohata N; Oshima Y; Minami Y; Shibata H; Itoh H
J Am Heart Assoc; 2018 Jun; 7(13):. PubMed ID: 29929989
[TBL] [Abstract][Full Text] [Related]
30. Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension.
Takeda Y
Hypertens Res; 2009 May; 32(5):321-4. PubMed ID: 19300447
[TBL] [Abstract][Full Text] [Related]
31. Spironolactone ameliorates arterial medial calcification in uremic rats: the role of mineralocorticoid receptor signaling in vascular calcification.
Tatsumoto N; Yamada S; Tokumoto M; Eriguchi M; Noguchi H; Torisu K; Tsuruya K; Kitazono T
Am J Physiol Renal Physiol; 2015 Dec; 309(11):F967-79. PubMed ID: 26336165
[TBL] [Abstract][Full Text] [Related]
32. Progestogens with antimineralocorticoid activity.
Losert W; Casals-Stenzel J; Buse M
Arzneimittelforschung; 1985; 35(2):459-71. PubMed ID: 4039568
[TBL] [Abstract][Full Text] [Related]
33. Glucocorticoid and mineralocorticoid receptors regulate paracellular permeability in a primary cultured gill epithelium.
Kelly SP; Chasiotis H
J Exp Biol; 2011 Jul; 214(Pt 14):2308-18. PubMed ID: 21697422
[TBL] [Abstract][Full Text] [Related]
34. Further studies in deoxycorticosterone acetate treated rats: brain content of mineralocorticoid and glucocorticoid receptors and effect of steroid antagonists on salt intake.
Vallee SM; Grillo CA; Gonzalez S; Cosen-Binker L; de Kloet ER; McEwen BS; De Nicola AF
Neuroendocrinology; 1995 Feb; 61(2):117-24. PubMed ID: 7753331
[TBL] [Abstract][Full Text] [Related]
35. The diuretic torasemide does not prevent aldosterone-mediated mineralocorticoid receptor activation in cardiomyocytes.
Gravez B; Tarjus A; Jimenez-Canino R; El Moghrabi S; Messaoudi S; Alvarez de la Rosa D; Jaisser F
PLoS One; 2013; 8(9):e73737. PubMed ID: 24040049
[TBL] [Abstract][Full Text] [Related]
36. Spironolactone decreases the somatic signs of opiate withdrawal by blocking the mineralocorticoid receptors (MR).
Navarro-Zaragoza J; Laorden ML; Milanés MV
Toxicology; 2014 Dec; 326():36-43. PubMed ID: 25308750
[TBL] [Abstract][Full Text] [Related]
37. Intact female stroke-prone hypertensive rats lack responsiveness to mineralocorticoid receptor antagonists.
Rigsby CS; Burch AE; Ogbi S; Pollock DM; Dorrance AM
Am J Physiol Regul Integr Comp Physiol; 2007 Oct; 293(4):R1754-63. PubMed ID: 17670862
[TBL] [Abstract][Full Text] [Related]
38. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
[TBL] [Abstract][Full Text] [Related]
39. Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure.
Sica DA
Methodist Debakey Cardiovasc J; 2015; 11(4):235-9. PubMed ID: 27057293
[TBL] [Abstract][Full Text] [Related]
40. Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism.
Karashima S; Yoneda T; Kometani M; Ohe M; Mori S; Sawamura T; Furukawa K; Seta T; Yamagishi M; Takeda Y
Hypertens Res; 2016 Mar; 39(3):133-7. PubMed ID: 26606875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
